 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Apr 28, 2023 |
| Title |
YTHDF2 inhibition potentiates radiotherapy by reprogramming suppressive myeloid cells |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
Methylation profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
37236197 |
| |
| Submission date |
Jun 17, 2022 |
| Last update date |
Jul 28, 2023 |
| Contact name |
Xiaoyang Dou |
| E-mail(s) |
xiaoyang.dou@sibcb.ac.cn
|
| Organization name |
Center for Excellence in Molecular Cell Science, CAS
|
| Street address |
320 Yue Yang Road
|
| City |
Shanghai |
| ZIP/Postal code |
200031 |
| Country |
China |
| |
|
| Platforms (2) |
| GPL21103 |
Illumina HiSeq 4000 (Mus musculus) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
| Samples (46)
|
| GSM6252809 |
WT, Control, Input, r2, RIP-seq |
| GSM6252810 |
WT, Control, Input, r3, RIP-seq |
| GSM6252811 |
WT, IR, Input, r1, RIP-seq |
| GSM6252812 |
WT, IR, Input, r2, RIP-seq |
| GSM6252813 |
WT, IR, Input, r3, RIP-seq |
| GSM6252814 |
WT, Control, YTHDF2 IP, r1, RIP-seq |
| GSM6252815 |
WT, Control, YTHDF2 IP, r2, RIP-seq |
| GSM6252816 |
WT, Control, YTHDF2 IP, r3, RIP-seq |
| GSM6252817 |
WT, IR, YTHDF2 IP, r1, RIP-seq |
| GSM6252818 |
WT, IR, YTHDF2 IP, r2, RIP-seq |
| GSM6252819 |
WT, IR, YTHDF2 IP, r3, RIP-seq |
| GSM6252826 |
Tumor, Control, mRNA-derived cDNA |
| GSM6252827 |
Tumor, Control, HTO-derived cDNA |
| GSM6252828 |
Tumor, IR, mRNA-derived cDNA |
| GSM6252829 |
Tumor, IR, HTO-derived cDNA |
| GSM6252830 |
Blood, Control, mRNA-derived cDNA |
| GSM6252831 |
Blood, Control, HTO-derived cDNA |
| GSM6252832 |
Blood, IR, mRNA-derived cDNA |
| GSM6252833 |
Blood, IR, HTO-derived cDNA |
| GSM6252848 |
WT, Control, Input, r1, MeRIP-seq |
| GSM6252849 |
WT, Control, Input, r2, MeRIP-seq |
| GSM6252850 |
WT, Control, Input, r3, MeRIP-seq |
| GSM6252851 |
WT, IR, Input, r1, MeRIP-seq |
| GSM6252852 |
WT, IR, Input, r2, MeRIP-seq |
| GSM6252853 |
WT, IR, Input, r3, MeRIP-seq |
| GSM6252854 |
Ythdf2 cKO, Control, Input, r1, MeRIP-seq |
| GSM6252855 |
Ythdf2 cKO, Control, Input, r2, MeRIP-seq |
| GSM6252856 |
Ythdf2 cKO, Control, Input, r3, MeRIP-seq |
| GSM6252857 |
Ythdf2 cKO, IR, Input, r1, MeRIP-seq |
| GSM6252858 |
Ythdf2 cKO, IR, Input, r2, MeRIP-seq |
| GSM6252859 |
Ythdf2 cKO, IR, Input, r3, MeRIP-seq |
| GSM6252860 |
WT, Control, m6A IP, r1, MeRIP-seq |
| GSM6252861 |
WT, Control, m6A IP, r2, MeRIP-seq |
| GSM6252862 |
WT, Control, m6A IP, r3, MeRIP-seq |
| GSM6252863 |
WT, IR, m6A IP, r1, MeRIP-seq |
| GSM6252864 |
WT, IR, m6A IP, r2, MeRIP-seq |
| GSM6252865 |
WT, IR, m6A IP, r3, MeRIP-seq |
| GSM6252866 |
Ythdf2 cKO, Control, m6A IP, r1, MeRIP-seq |
| GSM6252867 |
Ythdf2 cKO, Control, m6A IP, r2, MeRIP-seq |
| GSM6252868 |
Ythdf2 cKO, Control, m6A IP, r3, MeRIP-seq |
| GSM6252869 |
Ythdf2 cKO, IR, m6A IP, r1, MeRIP-seq |
| GSM6252870 |
Ythdf2 cKO, IR, m6A IP, r2, MeRIP-seq |
| GSM6252871 |
Ythdf2 cKO, IR, m6A IP, r3, MeRIP-seq |
|
| This SuperSeries is composed of the following SubSeries:
|
| GSE206378 |
YTHDF2 inhibition potentiates radiotherapy by reprogramming suppressive myeloid cells [scRNA-Seq] |
| GSE206379 |
YTHDF2 inhibition potentiates radiotherapy by reprogramming suppressive myeloid cells [RIP-Seq] |
| GSE206381 |
YTHDF2 inhibition potentiates radiotherapy by reprogramming suppressive myeloid cells [CITE-Seq] |
| GSE206384 |
YTHDF2 inhibition potentiates radiotherapy by reprogramming suppressive myeloid cells [MeRIP-Seq] |
|
| Relations |
| BioProject |
PRJNA850417 |
|
|
|
|
 |
Less...
More...